Global Indemnity Limited Announces Additional Share Redemption and Dividend Program
Dec 27, 2017 21:05 pm UTC| Business
GEORGE TOWN, Cayman Islands, Dec. 27, 2017 -- Global Indemnity Limited (NASDAQ:GBLI) announced today that it will acquire on December 29, 2017 3,397,031 of its A ordinary shares for approximately $83 million in the...
Veteran Financial Expert Rejoins Superconductor Technologies Board of Directors
Dec 27, 2017 21:05 pm UTC| Business
AUSTIN, Texas, Dec. 27, 2017 -- Superconductor Technologies Inc. (STI) (Nasdaq:SCON) announced the appointment of David Vellequette to its board of directors effective December 26, 2017. Vellequette, 61, previously...
Live Ventures Announces Fiscal Year-End 2017 Results
Dec 27, 2017 21:05 pm UTC| Business
LAS VEGAS, Dec. 27, 2017 -- Live Ventures Incorporated (Nasdaq:LIVE), a diversified holding company, today announced financial results from its fiscal year ended September 30, 2017. Reporting its most successful year...
Euroseas Ltd. Announces Delivery of Acquired Container Vessel and Sale of Feeder Container Vessel
Dec 27, 2017 21:05 pm UTC| Business
MAROUSSI, ATHENS, Greece , Dec. 27, 2017 -- Euroseas Ltd. (NASDAQ:ESEA) (the “Company”), an owner and operator of drybulk and container carrier vessels and provider of seaborne transportation for drybulk and...
Digirad Announces Sale of its MDSS Service Contracts to Philips North America
Dec 27, 2017 21:05 pm UTC| Business
SUWANEE, Ga., Dec. 27, 2017 -- Digirad Corporation (Nasdaq:DRAD) (the “Company”) today announced that it has entered into a definitive purchase agreement (“the Agreement”) with Philips North America (“Philips”) to sell...
Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering
Dec 27, 2017 21:01 pm UTC| Business
NEWTON, Mass., Dec. 27, 2017 -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with...
Dec 27, 2017 21:00 pm UTC| Business
Emotional health/self-perception issues were most common; limitations of lifestyle and activities as well as coping strategies were also important Provectus Biopharmaceuticals expands pivotal Phase 3 trial of intralesional...